For lifelong conditions like osteoporosis, drugs whose effects plateau after 1-2 years create treatment uncertainty for patients and providers. The goal should be therapies that provide a sustained, linear benefit without a ceiling. This is achieved by respecting the body's natural biology (e.g., bone remodeling) while precisely intervening only in the disease process.
The decision to found Skeletalis wasn't driven by a single lab breakthrough. Instead, it was the convergence of two distinct observations: clinically seeing patients' fear of existing drug side effects, and academically noticing a major gap at conferences between advanced animal model research and its translation into new human therapies.
Skeletalis CEO Ben Swanson explains how his dual DDS/PhD path, particularly treating patients with bone diseases, provided a unique perspective on their needs beyond a new mechanism of action. This clinical empathy for the "end user's" lifestyle, safety concerns, and desire for durability became a core driver for his company's R&D strategy.
After major pharma abandoned osteoporosis R&D due to costly trial failures, the field is experiencing a renaissance. The FDA's SABER initiative approved bone mineral density as a surrogate endpoint for registrational trials, slashing clinical trial sizes (e.g., from 15k to 1.5k patients), timelines, and costs, de-risking the space for new investment.
Skeletalis's platform targets osteoporosis with precision using "site-specific pharmacology." A small molecule anchors an inactive prodrug to the bone, where it is activated only by the cells causing bone loss. This localized approach dramatically improves the safety profile and therapeutic index, enabling the use of novel biological targets that would be too risky for systemic delivery.
The transition from academia to a startup can be viewed as an acceleration of the same mission. While academic grants are written about solving problems for millions, building a company offers a direct, focused, and "freeing" path to actually delivering a solution to those patients, who serve as the consistent "North Star" across both worlds.